End-to-End AAV CMC & Scalable Biomanufacturing Platform
Translating breakthrough AAV gene therapies from benchtop innovation to commercial reality requires a robust, scalable, and highly reproducible Chemistry, Manufacturing, and Controls (CMC) strategy. However, conventional AAV bioprocessing often encounters severe commercialization bottlenecks—including low upstream yield, high percentages of empty capsids, batch-to-batch heterogeneity, and steep manufacturing costs that limit patient accessibility.
To overcome these industrial hurdles, Protheragen introduces a fully integrated, end-to-end AAV manufacturing and bioprocessing platform. Leveraging our advanced packaging engine, proprietary high-density cell culture technologies, and refined multi-column purification processes, our platform ensures seamless scale-up, superior vector purity, and strict regulatory compliance from early-stage research (IIT) through registrational clinical trials and commercial production.
Fig.1 General workflow of AAV vector manufacturing. (Kowshik, et al., 2025)
Technical Breakthroughs
- Cost-Effective Packaging Engine
Replaces traditional three-plasmid transfection systems with our innovative two-plasmid system for suspended HEK293 cells. This dramatically simplifies the transfection process, improves packaging efficiency, increases batch consistency, and substantially lowers raw material costs (COGS).
- High Full-Capsid Separation Technology
Utilizes a proprietary multi-step purification process combining density-gradient centrifugation with high-resolution chromatography. This ensures consistently ultra-high full-capsid ratios (>90%), minimizing empty/partial capsids and reducing vector-induced immunogenicity in clinical applications.
- Seamless Bench-to-Scale Bioprocessing
Establishes a robust, closed-system bioprocessing workflow. Facilitates smooth, risk-free technology transfer and seamless volume scale-up from lab-scale shake flasks (milliliter scale) to cGMP-compliant mid-to-large scale bioreactors (hundred-liter scale).
Platform Advantages
- Commercial-Grade Manufacturability
Engineered for rapid scale-up with high reproducibility, dramatically shortening clinical development timelines.
- Ultra-High Purity & Safety
Consistently achieves >90% full-capsid enrichment with minimal host cell DNA (HCD), host cell protein (HCP), and helper virus residues.
- Significant COGS Reduction
Dual-plasmid design and high-yield bioprocessing significantly reduce manufacturing costs per dose.
- Regulatory Compliance & Traceability
Designed in full alignment with NMPA, FDA, and EMA cGMP guidelines for seamless filing.
Platform Capabilities
Upstream Cell Culture & Fermentation
Optimized triple/double transfection in high-density adherent and suspension HEK293 systems.
Downstream Purification & Processing
Advanced tangential flow filtration (TFF), affinity chromatography, and anion-exchange (AEX) separation.
Formulation & Stability Development
Custom formulation optimization for long-term vector stability across frozen and liquid cold-chain storage.
Complete Tech Transfer & Scale-Up
Comprehensive process characterization, validation, and tech transfer documentation for clinical and commercial supply.
Solutions Across Biopharmaceutical Development
Protheragen's platform provides tailored end-to-end CDMO/CRO solutions across diverse phase-specific requirements:
Preclinical & IIT Fast-Track Supply
- Rapid, flexible small-to-medium batch manufacturing for Proof-of-Concept (PoC) studies.
- High-titer, research-grade and cGMP-grade vector batches for Investigator-Initiated Trials (IITs).
Clinical Trial Material (CTM) Manufacturing
- Strict cGMP production for Phase I/II/III registrational clinical trials.
- Comprehensive batch release testing, stability monitoring, and chemistry/manufacturing dossiers support.
Commercial Scale-Up & BLA Support
- Large-scale bioreactor runs for commercial supply.
- Process validation, comparability studies, and regulatory submission support.
Protheragen offers an integrated, one-stop CMC and manufacturing platform designed to bridge the gap between discovery and commercial success. By uniting advanced biomanufacturing technologies with rigorous quality control, we help biopharmaceutical partners minimize risk, lower production costs, and accelerate the delivery of life-changing AAV gene therapies to patients globally.
Contact our CMC and bioprocessing experts today to discuss your AAV manufacturing strategy, request process optimization, or schedule a custom proposal.
Reference
- Kowshik, N Charan S S, and Pushpendra Singh. "Advancing AAV vector manufacturing: challenges, innovations, and future directions for gene therapy." Frontiers in molecular medicine vol. 5 1709095. 3 Dec. 2025.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
